Cangrelor Tetrasodium

Cangrelor Tetrasodium (CAS No.: 163706-36-3) is a synthetic nucleotide analog widely classified as a platelet signaling modulator and receptor pharmacology tool compound for cardiovascular and thrombosis related research, characterized by reversible and selective antagonism of the purinergic P2Y12 receptor with additional reported nonselective antagonistic activity at GPR17, thereby directly suppressing ADP triggered platelet activation, granule secretion, and aggregation cascades in experimental systems and providing a robust mechanistic probe for studying purinergic control of hemostatic cell responses; within biomedical research workflows it is primarily used to interrogate P2Y12 dependent intracellular signaling networks, including modulation of Gi coupled pathways that regulate cyclic AMP associated signaling tone and downstream platelet functional outputs, and published preclinical pharmacology descriptions generally indicate activity in the nanomolar to micromolar range depending on assay format, receptor context, and species background, while common applications include in vitro platelet function assays, ex vivo blood based aggregation studies, and animal model investigations of thrombus formation biology as well as reference standard use in antiplatelet mechanism based drug screening programs, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.